Cristina Csimma, PharmD, MHP
Cristina Csimma, PharmD, MHP, is a biopharmaceutical executive with fund raising, new company formation and drug development expertise in the biopharmaceutical industry, venture capital and academic settings. She serves on the Board of Directors of Juniper Pharmaceuticals and Neuralstem, Inc.; the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee; the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network; the External Oversight Committee of NIH Blueprint Neurotherapeutics Network; and the Harvard and Brigham and Women’s Hospital MRCT Center External Advisory Board. She was previously Executive Chair of the Board of Directors of Exonics, Board Director at Vtesse Inc. (acquired by Sucampo Pharmaceuticals) and Cydan, where she was also President and founding CEO. Prior appointments include Vice President of Drug Development at Virdante Pharmaceuticals Inc., Principal at Clarus Ventures LLC, program leadership in Clinical Development and Translational Research at Wyeth (now Pfizer), Genetics Institute, Inc., and clinical pharmacist at Dana Farber Cancer Institute. Dr. Csimma received her Bachelor of Science and Doctor of Pharmacy degrees from Massachusetts College of Pharmacy and Health Sciences, and a Master of Health Professions from Northeastern University.